Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

por Dredge, K, Marriott, J B, Macdonald, C D, Man, H-W, Chen, R, Muller, G W, Stirling, D, Dalgleish, A G
Publicado 2002

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced...

por Bartlett, J B, Michael, A, Clarke, I A, Dredge, K, Nicholson, S, Kristeleit, H, Polychronis, A, Pandha, H, Muller, G W, Stirling, D I, Zeldis, J, Dalgleish, A G
Publicado 2004